ArticleInternational journal of preventive medicine2025
Selegiline Improved Oxidative and Inflammatory Stress Factors in Gentamicin-Induced Nephrotoxicity in Human Renal Tubular Epithelial Cells.
Article in International journal of preventive medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gentamicin, an effective antibiotic, can lead to kidney damage through increased oxidative stress and inflammation. As a monoamine oxidase inhibitor, selegiline has antioxidant and anti-inflammatory properties that may reduce the negative effects of gentamicin. Method: This study was conducted on human kidney tubular cells (HEK) and divided into five groups, control, group of cells exposed to gentamicin, group of cells exposed to gentamicin+ 20 μmol selegiline treatment, group of cells exposed to gentamicin + treatment of cells with selegiline 30 μmol, and group of cells exposed to gentamicin + treatment of cells with selegiline 40 μmol were placed, and in all groups, the amount of gentamicin was 3 μmol. Results: This research showed that selegiline increases cell viability, total antioxidant capacity, and interleukin 10 as well as decreases the amount of reactive oxygen species, malondialdehyde, and interleukin 6 against the effects of gentamicin-induced nephrotoxicity. Conclusions: These findings show that selegiline can have protective effects on kidney damage caused by gentamicin and by reducing oxidative stress and inflammation, it can be proposed as a promising treatment option to reduce the side effects of gentamicin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.